Overview of the drug development pipeline for nosocomial pneumonia
It has been observed that nosocomial pneumonia is an acute lower respiratory tract infection. Hospital-acquired pneumonia (HAP) or nosocomial pneumonia is generally referred to pneumonia contracted by a patient in a hospital after getting admitted for at least two to three days. The causes of nosocomial pneumonia are a variety of pathogens, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, and methicillin-resistant S. aureus (MRSA). The common symptoms of nosocomial pneumonia are cold, sore throat, fever and chills, malaise, shortness of breath, and sharp chest pain that increases with coughing. The most effective approach for the treatment of nosocomial pneumonia is emerging to be monotherapy.
According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for nosocomial pneumonia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Drug development pipeline report for nosocomial pneumonia: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of nosocomial pneumonia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- Achaogen
- Aridis Pharmaceuticals
- Basilea Pharmaceutica
Therapeutic assessment of the drug development pipeline for nosocomial pneumonia by route of administration
- IV
- Oral
- Inhalation
- IV or oral
- Unknown
The IV route of administration (ROA) involves the administration of the drug directly into the veins as a liquid substance and in the oral technique, the molecules are delivered directly into the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for nosocomial pneumonia by therapy
- Monotherapy
- Combination therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for nosocomial pneumonia are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the gene therapy molecules in the various development stages for nosocomial pneumonia?
- What are the companies that are currently involved in the development of drug molecules for nosocomial pneumonia?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX